Trial · NCT05060016
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 17 of 17
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 61 months | |
| Primary | Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events | Up to a maximum of 61 months | |
| Primary | Part 1 Only: Serum Concentrations of Tarlatamab | Up to a maximum of 24 months | |
| Primary | Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 61 months | |
| Secondary | Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months | |
| Secondary | Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months | |
| Secondary | Duration of Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months | |
| Secondary | Progression-free Survival (PFS) Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR) | Up to a maximum of 73 months | |
| Secondary | Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months | |
| Secondary | Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months | |
| Secondary | Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months | |
| Secondary | Duration of Disease Control (DC) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months | |
| Secondary | Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months | |
| Secondary | Overall Survival (OS) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator | Up to a maximum of 73 months | |
| Secondary | Number of Participants who Experience One or More Treatment-emergent Adverse Events | Up to a maximum of 73 months | |
| Secondary | Serum Concentrations of Tarlatamab | Up to a maximum of 24 months | |
| Secondary | Number of Participants who Experience Anti-Tarlatamab Antibody Formation | Up to a maximum of 73 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05060016/registered